Business Context and Reporting Period
Company: Alaunos Therapeutics, Inc. (TCRT)
Filing Type: Form 8-K (Current Report)
Date of Report: April 9, 2026
Event: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard.
Key Financial Metrics
The filing discloses specific equity figures derived from the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025:
- Stockholders' Equity: $2,153,000
- Nasdaq Minimum Equity Requirement: $2,500,000
- Market Value of Listed Securities: Below the $35 million alternative standard.
- Net Income: Below the $500,000 alternative standard for the most recent fiscal year and two of the last three fiscal years.
Note: The filing does not provide specific values for revenue, cash flow, operating margins, or total debt.
Material Changes and Non-Compliance
On April 9, 2026, the Company received a written notice from Nasdaq stating it is not in compliance with Listing Rule 5550(b)(1) due to insufficient stockholders' equity. The reported equity of $2,153,000 falls short of the required $2,500,000. Additionally, the Company fails to meet the alternative continued listing standards regarding market value of listed securities or net income from continuing operations.
Outlook, Management Commentary, and Risks
- Compliance Timeline: The Company has 45 calendar days (until May 26, 2026) to submit a plan to regain compliance.
- Extension Possibility: If a plan is accepted, Nasdaq may grant an extension of up to 180 calendar days to evidence compliance.
- Management Action: The Company intends to submit a compliance plan and is evaluating potential actions to regain compliance.
- Risks: There is no assurance that the plan will be accepted or that the Company will regain compliance within any granted extension period.
- Delisting Process: If the plan is rejected or compliance is not achieved, the Company has the right to request a hearing before an independent Nasdaq hearings panel, which would stay any suspension or delisting action pending the conclusion of the hearing.
- Trading Status: Trading in the Company's securities is expected to continue following this disclosure.
Investor Verification Checklist
- Verify the Company's submission of a compliance plan to Nasdaq by May 26, 2026.
- Monitor Nasdaq's decision on the acceptance of the compliance plan and any granted extension periods.
- Review the Company's financial statements to understand the specific drivers of the negative stockholders' equity.
- Assess the Company's capital raising activities or operational changes intended to restore equity levels.
- Watch for any subsequent filings regarding a hearing request if the initial compliance plan is rejected.